Characteristics of patients in this study
| . | With craniofacial involvement n = 290 . | Without craniofacial involvement n = 3865 . | P value . |
|---|---|---|---|
| Sex | .008 | ||
| M | 184 (63.4%) | 2141 (55.4%) | |
| F | 106 (36.6%) | 1724 (44.6%) | |
| Age median (range) | 64 (18; 79) | 58 (18; 80) | <.001 |
| Age >60 | 169 (58.3%) | 1737 (44.9%) | <.001 |
| ECOG >1 | 9 (3.1%) | 485 (12.6%) | <.001 |
| Stage III/IV | 88 (30.3%) | 1773 (45.9%) | <.001 |
| LDH > UNV | 52 (17.9%) | 1688 (43.7%) | <.001 |
| Extralymphatic involvement >1* | 102 (35.2%) | 664 (17.2%) | <.001 |
| Bulk ≥7.5 cm | 46 (15.9%) | 1695 (43.9%) | <.001 |
| IPI = 0, 1* | 173 (59.7%) | 2057 (53.3%) | |
| IPI = 2 | 52 (17.9%) | 814 (21.1%) | .087 |
| IPI = 3 | 46 (15.9%) | 606 (15.7%) | |
| IPI = 4, 5 | 19 (6.6%) | 385 (10.0%) | |
| Lymphoblastic precursor B cell* | 0 (0.0%) | 6 (0.2%) | |
| Diffuse large B cell* | 235 (81.0%) | 3152 (81.6%) | |
| Centroblastic | 150 (51.7%) | 1669 (43.2%) | |
| Immunoblastic | 20 (6.9%) | 215 (5.6%) | |
| Plasmablastic | 3 (1.0%) | 13 (0.3%) | |
| Anaplastic large cell | 1 (0.3%) | 91 (2.4%) | |
| T-cell–rich B-cell lymphoma | 1 (0.3%) | 102 (2.6%) | |
| Mediastinal B cell | 0 (0.0%) | 219 (5.7%) | |
| DLBCL, NOS | 60 (20.7%) | 843 (21.8%) | |
| Primary effusion lymphoma* | 0 (0.0%) | 1 (<0.1%) | |
| Follicular lymphoma grade IIIb | 9 (3.1%) | 182 (4.7%) | |
| Follicular lymphoma grade III + DLBCL* | 8 (2.8%) | 143 (3.7%) | |
| Burkitt lymphoma* | 4 (1.4%) | 19 (0.5%) | |
| Burkitt-like* | 7 (2.4%) | 44 (1.1%) | |
| Mantle cell lymphoma (blastic)* | 4 (1.4%) | 38 (1.0%) | |
| Aggressive marginal zone lymphoma* | 6 (2.1%) | 36 (0.9%) | |
| NOS* | 12 (4.1%) | 118 (3.1%) | |
| B cell (unclassified, technically insufficient)* | 5 (1.7%) | 126 (3.3%) |
| . | With craniofacial involvement n = 290 . | Without craniofacial involvement n = 3865 . | P value . |
|---|---|---|---|
| Sex | .008 | ||
| M | 184 (63.4%) | 2141 (55.4%) | |
| F | 106 (36.6%) | 1724 (44.6%) | |
| Age median (range) | 64 (18; 79) | 58 (18; 80) | <.001 |
| Age >60 | 169 (58.3%) | 1737 (44.9%) | <.001 |
| ECOG >1 | 9 (3.1%) | 485 (12.6%) | <.001 |
| Stage III/IV | 88 (30.3%) | 1773 (45.9%) | <.001 |
| LDH > UNV | 52 (17.9%) | 1688 (43.7%) | <.001 |
| Extralymphatic involvement >1* | 102 (35.2%) | 664 (17.2%) | <.001 |
| Bulk ≥7.5 cm | 46 (15.9%) | 1695 (43.9%) | <.001 |
| IPI = 0, 1* | 173 (59.7%) | 2057 (53.3%) | |
| IPI = 2 | 52 (17.9%) | 814 (21.1%) | .087 |
| IPI = 3 | 46 (15.9%) | 606 (15.7%) | |
| IPI = 4, 5 | 19 (6.6%) | 385 (10.0%) | |
| Lymphoblastic precursor B cell* | 0 (0.0%) | 6 (0.2%) | |
| Diffuse large B cell* | 235 (81.0%) | 3152 (81.6%) | |
| Centroblastic | 150 (51.7%) | 1669 (43.2%) | |
| Immunoblastic | 20 (6.9%) | 215 (5.6%) | |
| Plasmablastic | 3 (1.0%) | 13 (0.3%) | |
| Anaplastic large cell | 1 (0.3%) | 91 (2.4%) | |
| T-cell–rich B-cell lymphoma | 1 (0.3%) | 102 (2.6%) | |
| Mediastinal B cell | 0 (0.0%) | 219 (5.7%) | |
| DLBCL, NOS | 60 (20.7%) | 843 (21.8%) | |
| Primary effusion lymphoma* | 0 (0.0%) | 1 (<0.1%) | |
| Follicular lymphoma grade IIIb | 9 (3.1%) | 182 (4.7%) | |
| Follicular lymphoma grade III + DLBCL* | 8 (2.8%) | 143 (3.7%) | |
| Burkitt lymphoma* | 4 (1.4%) | 19 (0.5%) | |
| Burkitt-like* | 7 (2.4%) | 44 (1.1%) | |
| Mantle cell lymphoma (blastic)* | 4 (1.4%) | 38 (1.0%) | |
| Aggressive marginal zone lymphoma* | 6 (2.1%) | 36 (0.9%) | |
| NOS* | 12 (4.1%) | 118 (3.1%) | |
| B cell (unclassified, technically insufficient)* | 5 (1.7%) | 126 (3.3%) |
ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; UNV, upper normal value.
According to reference pathology.